Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / LMDX - LumiraDx COVID-19 & Flu rapid antigen test secures CE marking

LMDX - LumiraDx COVID-19 & Flu rapid antigen test secures CE marking

LumiraDx Limited
LumiraDx (NASDAQ:LMDX) announces that its SARS-CoV-2 & Flu A/B Antigen Test has achieved CE Marking. The microfluidic immunofluorescence assay can quickly verify potential infection for patients suspected of influenza and/or COVID-19. Existing respiratory tests on the LumiraDx Platform include the company's SARS-CoV-2 Antigen, SARS-CoV-2 Antibody and SARS-CoV-2 Antigen Pool tests which achieved CE Marking in August 2020, September 2020 and March 2021, respectively. Shipments of the LumiraDx SARS-CoV-2 & Flu A/B Antigen Test will begin shortly. Earlier this month, FDA reissued the emergency use authorization for LMDX's COVID-19 testing solution.

For further details see:

LumiraDx COVID-19 & Flu rapid antigen test secures CE marking
Stock Information
Company Name: LumiraDx Limited
Stock Symbol: LMDX
Market: NASDAQ
Menu
LMDX LMDX Quote LMDX Short LMDX News LMDX Articles LMDX Message Board
Get LMDX Alerts

News, Short Squeeze, Breakout and More Instantly...